<DOC>
	<DOCNO>NCT00850096</DOCNO>
	<brief_summary>The purpose study : - To assess efficacy Nasulin vs. placebo indicated time spend euglycemia , assess continuous glucose monitoring data serum fructosamine level patient volunteer Type 2 Diabetes . - To asses safety tolerability Nauslin 50 IU 100IU dos patient volunteer Type 2 Diabetes</brief_summary>
	<brief_title>Effects Nasulin Versus Placebo Blood Glucose Control Patient Volunteers With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This proof concept trial randomize , parallel , double-blind , placebo-controlled design 4-week single-blind placebo diet run-in period . Given ratio 1:1 , patient volunteer randomize one two parallel treatment arm , Nasulin combination insulin glargine placebo combination insulin glargine . The randomization period 6 week length . The total length individual patient volunteer participation , include screen follow-up approximately 13-14 week .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Adults Type 2 diabetes ( 18 year age old ) Currently treat basal insulin OAD ( ) HbA1c range 6.5 10 . BMI le 41 Multiple daily injection mealtime insulin Regular use nasal spray Significant nasal pathology Employed job require irregular shift night work</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Phase 2 Study novel insulin delivery type 2 diabetes</keyword>
</DOC>